AbCellera @AbCelleraBio · 10 Aug 2026
AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile https://t.co/SaKBMfviO7 https://t.co/9DqVz3h0c4
108 851Views
581Likes
120Reposts
40Replies
52Quotes
20Bookmarks
Is that a lot?
100×vs this author's median1 086 views is typical
75Percentile for this authorof 4 recent posts
37.5×vs under 10K median2 899 views is typical
13.7× audienceReachviews ÷ followers
0.73%Engagement rateof viewers reacted